Researchers have made a groundbreaking discovery in the field of rare neurodegenerative diseases, offering a glimmer of hope to families affected by a severe condition known as DHDDS. This condition, characterized by tremors, seizures, coordination and learning difficulties, typically manifests in early childhood, leaving parents with limited options and a sense of helplessness. However, a collaborative effort between researchers from The Netherlands and the US has led to a remarkable breakthrough.
The story begins with two parents who reached out to Dr. Irena Muffels, a clinical genetics resident at the Wilhemina Children's Hospital in Utrecht, The Netherlands. These parents had been diagnosed with DHDDS in their children and were desperate for any solution to slow down the disease's progression. Their determination sparked a journey that would change the landscape of rare disease research.
Dr. Muffels and her team created 'mini-brains'—tiny, lab-grown brain tissue models derived from the patients' own cells. This innovative approach allowed them to study the disease mechanism and progression in a controlled environment, avoiding the need for invasive brain samples from the children. The mini-brains revealed a crucial insight: the DHDDS gene plays a vital role in producing dolichol, a small lipid anchor that carries sugar and helps build glycans, which are essential for protein function.
The researchers discovered that in the DHDDS mini-brains, dolichol production was severely reduced, leading to mistakes in glycans' construction. This, in turn, affected lipid metabolism and resulted in significant cholesterol build-up in astrocytes, brain cells responsible for neuroprotection. The accumulation of cholesterol over time was identified as the primary reason for the disease's progression, causing mitochondrial dysfunction and reduced energy production.
A collaboration with the biotech company Perlara led to an exciting discovery. They screened FDA-approved drugs and vitamins, and found that nicotinamide mononucleotide (NMN), a naturally occurring form of vitamin B3, showed remarkable promise. NMN was tested in the mini-brains, and the results were astonishing. The vitamin seemed to slow down the disease's progression, improving patients' walking ability, energy levels, and overall movement.
The potential of NMN extends beyond DHDDS. It has already shown positive effects in patients with mitochondrial disease and Parkinson's disease. High doses of NMN have been linked to slowed progression and reduced symptom burden. This broad spectrum of benefits suggests that NMN could be a game-changer for various genetic metabolic disorders affecting energy production in the brain.
Encouraged by the initial findings, Dr. Muffels and her team initiated an international trial for NMN supplementation in DHDDS-related disease. They are evaluating 12 patients every three months, and the results have been promising. Some patients have shown significant improvements, with reduced symptoms and enhanced quality of life. The trial's success has sparked hope among families affected by DHDDS.
The accessibility and affordability of NMN, coupled with its lack of known side-effects, make it an attractive option for rare disease treatment. The collaboration between parents, charities, and academics has played a pivotal role in bringing this promising therapy to the forefront. As the research continues, the future holds the potential for improved quality of life for those affected by DHDDS and other rare neurodegenerative diseases.
